Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc. is listed today as Agios Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2011 | $78 M | No. 2 | $50 to $250 million | equity | SEC | |
| Apr 2010 | $9 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Agios Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2011).
SEC Form D · Nov 2011
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2011
That is all the official record says: Agios Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Agios Pharmaceuticals Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Celgene Corp /de/ | Company | not stated | not stated | Held Series B and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Celgene European Investment Co LLC | Fund or asset manager | not stated | not stated | Held Series B and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures 2007 General Partner LLC | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures Fund 2007, L.P. | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series A and C-2 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 19 investors.
Largest shareholders today
Institutions holding Agios Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$207 M10.41%
- Farallon Capital Management, L.L.C.$197 M9.93%
- D. E. Shaw & Co., Inc.$129 M6.50%
- Morgan Stanley$114 M5.75%
- State Street Corp$109 M5.46%
- Vanguard Portfolio Management LLC$95 M4.77%
- Vanguard Capital Management LLC$89 M4.49%
- Armistice Capital, LLC$86 M4.31%
- Nomura Asset Management International Inc.$65 M3.27%
- Assenagon Asset Management S.A.$63 M3.15%
- Erste Asset Management GmbH$60 M3.02%
- Geode Capital Management, LLC$53 M2.65%
- GW&K Investment Management, LLC$46 M2.33%
- Susquehanna International Group, LLP$44 M2.21%
- Dimensional Fund Advisors LP$43 M2.15%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Schenkein | Executive officer | Nov 2011 |
| Duncan Higgons | Executive officer | Nov 2011 |
| David Schenkein | Director | Nov 2011 |
| Doug Cole | Director | Nov 2011 |
| John C. Maraganore | Director | Nov 2011 |
| Kevin C. Starr | Director | Nov 2011 |
| Lewis C. Cantley | Director | Nov 2011 |
| Marc C. Tessier-Lavigne | Director | Nov 2011 |
| Perry C. Karsen | Director | Nov 2011 |
| Robert Nelsen | Director | Nov 2011 |
About
A public American pharmaceutical company.
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.